MARY EVANS: Open Payments
NPI 1508948340 · MONTGOMERY, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$959 in 48 payments from 21 companies in 2025. Trend: 2023 $820 · 2024 $1,661 · 2025 $959
Food & beverage: $959
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $257 |
| AstraZeneca Pharmaceuticals LP | 8 | $162 |
| Abbott Laboratories | 3 | $66 |
| Lilly USA, LLC | 3 | $52 |
| Novartis Pharmaceuticals Corporation | 3 | $49 |
| Sumitomo Pharma America, Inc. | 3 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Amgen Inc. | 2 | $36 |
| SHIELD THERAPEUTICS INC | 2 | $33 |
Products named: QULIPTA, FARXIGA, FREESTYLE LIBRE 3, UBRELVY, LEQVIO, GEMTESA, CAPLYTA, Auvelity.
Industry payments across AL — which companies pay providers there.
